Company news
MacroGenics, Inc. news in 2020
MacroGenics, Inc.'s news releases, calls and decks from 2020, newest first.
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
December 21, 2020
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
December 17, 2020
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
December 15, 2020
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
November 29, 2020
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
November 29, 2020
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
November 3, 2020
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
November 3, 2020
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
October 27, 2020
MacroGenics Announces Flotetuzumab Publication in Blood Advances
October 14, 2020
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
September 22, 2020
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
September 21, 2020
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
September 20, 2020
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
September 19, 2020
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
July 29, 2020
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
July 22, 2020
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
July 8, 2020
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
June 21, 2020
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer
June 15, 2020
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
June 4, 2020
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
May 27, 2020
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
May 26, 2020
MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
May 20, 2020
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
May 12, 2020
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
May 4, 2020
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
April 28, 2020
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
April 27, 2020
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
April 27, 2020
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
April 26, 2020
MacroGenics Announces Departure of Chief Medical Officer
March 3, 2020
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
February 24, 2020
MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
February 12, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (December 2020)
Investor deck · 14 slides · Dec 17, 2020
- ASCO 2020
Conference · 18 slides · May 29, 2020
- ESMO 2020
Conference · 13 slides · 2020